Pragmatic, open-label, single-center, randomized, phase II clinical trial to evaluate the efficacy and safety of methylprednisolone pulses and tacrolimus in patients with severe pneumonia secondary to COVID-19: the TACROVID trial protocol

X Solanich, A Antolí, N Padullés, M Fanlo-Maresma, A Iriarte, F Mitjavila, O Capdevila, M Molina, J Sabater, J Bas, A Mensa-Vilaró, J Niubó, N Calvo, S Bolivar, R Rigo-Bonnin, L Arregui, C Tebé, P Hereu, S Videla, X Corbella
doi: https://doi.org/10.1101/2021.01.09.21249263

Article Information

doi 
https://doi.org/10.1101/2021.01.09.21249263
History 
  • January 12, 2021.
Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.

Author Information

  1. X Solanich1,*,
  2. A Antolí1,
  3. N Padullés2,
  4. M Fanlo-Maresma1,
  5. A Iriarte1,
  6. F Mitjavila1,
  7. O Capdevila1,
  8. M Molina3,
  9. J Sabater4,
  10. J Bas5,
  11. A Mensa-Vilaró6,
  12. J Niubó7,
  13. N Calvo8,
  14. S Bolivar8,
  15. R Rigo-Bonnin9,
  16. L Arregui10,
  17. C Tebé11,
  18. P Hereu12,13,
  19. S Videla12,13 and
  20. X Corbella1,14
  1. 1Departments of Internal Medicine, University of Barcelona, L’Hospitalet de Llobregat, Barcelona, Spain
  2. 2Departments of Pharmacy, University of Barcelona, L’Hospitalet de Llobregat, Barcelona, Spain
  3. 3Departments of Respiratory Medicine, University of Barcelona, L’Hospitalet de Llobregat, Barcelona, Spain
  4. 4Departments of Intensive Medicine, University of Barcelona, L’Hospitalet de Llobregat, Barcelona, Spain
  5. 5Departments of Immunology, University of Barcelona, L’Hospitalet de Llobregat, Barcelona, Spain
  6. 6Immunology Service, Hospital Clínic, Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain
  7. 7Departments of Microbiology, University of Barcelona, L’Hospitalet de Llobregat, Barcelona, Spain
  8. 8Departments of Diagnostic Imaging, University of Barcelona, L’Hospitalet de Llobregat, Barcelona, Spain
  9. 9Departments of Clinical Laboratory, University of Barcelona, L’Hospitalet de Llobregat, Barcelona, Spain
  10. 10Departments of BUH-ICO-IDIBELL Biobank, Bellvitge Biomedical Research Institute (IDIBELL), L’Hospitalet de Llobregat, Barcelona, Spain
  11. 11Departments of Statistics, Bellvitge Biomedical Research Institute (IDIBELL), L’Hospitalet de Llobregat, Barcelona, Spain
  12. 12Departments of Clinical Pharmacology, Bellvitge University Hospital, Bellvitge Biomedical Research Institute (IDIBELL), University of Barcelona, L’Hospitalet de Llobregat, Barcelona, Spain
  13. 13Departments of Clinical Research and Clinical Trial Unit (UICEC-IDIBELL), Plataforma SCRen, Bellvitge Biomedical Research Institute (IDIBELL), L’Hospitalet de Llobregat, Barcelona, Spain
  14. 14Evaluation of Health Determinants and Health Policies Group, Hestia Chair in Integrated Health and Social Care, School of Medicine, Universitat Internacional de Catalunya, Barcelona, Spain
  1. ↵*CORRESPONDING AUTHOR Xavier Solanich, MD
    , Department of Internal Medicine, Bellvitge University Hospital, Bellvitge Biomedical Research Institute (IDIBELL), 08907 L’Hospitalet de Llobregat (Barcelona), Spain, Phone: 0034 96 260 2324, Fax: 0034 93 260 7967, Email: xsolanich{at}bellvitgehospital.cat
Back to top
Posted January 12, 2021.
Download PDF
Data/Code
Email
Pragmatic, open-label, single-center, randomized, phase II clinical trial to evaluate the efficacy and safety of methylprednisolone pulses and tacrolimus in patients with severe pneumonia secondary to COVID-19: the TACROVID trial protocol
X Solanich, A Antolí, N Padullés, M Fanlo-Maresma, A Iriarte, F Mitjavila, O Capdevila, M Molina, J Sabater, J Bas, A Mensa-Vilaró, J Niubó, N Calvo, S Bolivar, R Rigo-Bonnin, L Arregui, C Tebé, P Hereu, S Videla, X Corbella
medRxiv 2021.01.09.21249263; doi: https://doi.org/10.1101/2021.01.09.21249263
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools

Subject Area